181 related articles for article (PubMed ID: 31462706)
1. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells.
Cebrià-Costa JP; Pascual-Reguant L; Gonzalez-Perez A; Serra-Bardenys G; Querol J; Cosín M; Verde G; Cigliano RA; Sanseverino W; Segura-Bayona S; Iturbide A; Andreu D; Nuciforo P; Bernado-Morales C; Rodilla V; Arribas J; Yelamos J; de Herreros AG; Stracker TH; Peiró S
Oncogene; 2020 Jan; 39(1):79-121. PubMed ID: 31462706
[TBL] [Abstract][Full Text] [Related]
2. LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells.
Serra-Bardenys G; Blanco E; Escudero-Iriarte C; Serra-Camprubí Q; Querol J; Pascual-Reguant L; Morancho B; Escorihuela M; Tissera NS; Sabé A; Martín L; Segura-Bayona S; Verde G; Aiese Cigliano R; Millanes-Romero A; Jerónimo C; Cebrià-Costa JP; Nuciforo P; Simonetti S; Viaplana C; Dienstmann R; Oliveira M; Peg V; Stracker TH; Arribas J; Canals F; Villanueva J; Di Croce L; García de Herreros A; Tian TV; Peiró S
FEBS J; 2024 Jun; 291(11):2423-2448. PubMed ID: 38451841
[TBL] [Abstract][Full Text] [Related]
3. Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3.
Herranz N; Dave N; Millanes-Romero A; Pascual-Reguant L; Morey L; Díaz VM; Lórenz-Fonfría V; Gutierrez-Gallego R; Jerónimo C; Iturbide A; Di Croce L; García de Herreros A; Peiró S
FEBS J; 2016 Dec; 283(23):4263-4273. PubMed ID: 27735137
[TBL] [Abstract][Full Text] [Related]
4. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE
Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800
[TBL] [Abstract][Full Text] [Related]
5. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
[TBL] [Abstract][Full Text] [Related]
6. Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.
Pascual-Reguant L; Serra-Camprubí Q; Datta D; Cianferoni D; Kourtis S; Gañez-Zapater A; Cannatá C; Espinar L; Querol J; García-López L; Musa-Afaneh S; Guirola M; Gkanogiannis A; Miró Canturri A; Guzman M; Rodríguez O; Herencia-Ropero A; Arribas J; Serra V; Serrano L; Tian TV; Peiró S; Sdelci S
EMBO Mol Med; 2023 Dec; 15(12):e18459. PubMed ID: 37937685
[TBL] [Abstract][Full Text] [Related]
7. Lysyl oxidase-like 2 deaminates lysine 4 in histone H3.
Herranz N; Dave N; Millanes-Romero A; Morey L; Díaz VM; Lórenz-Fonfría V; Gutierrez-Gallego R; Jerónimo C; Di Croce L; García de Herreros A; Peiró S
Mol Cell; 2012 May; 46(3):369-76. PubMed ID: 22483618
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of the promoter of cancer-related gene LOXL2.
Liu X; Liu T; Hu L; Jiang T; Liu H; Wang Y; Lei Y; Zhu J; Bu Y
Exp Cell Res; 2020 Feb; 387(2):111786. PubMed ID: 31870772
[TBL] [Abstract][Full Text] [Related]
9. LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.
Choi SK; Kim HS; Jin T; Moon WK
Oncotarget; 2017 Feb; 8(7):11977-11989. PubMed ID: 28060764
[TBL] [Abstract][Full Text] [Related]
10. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
11. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Processing of Lysyl Oxidase-like 2 and Its Effect on Amine Oxidase Activity.
Okada K; Moon HJ; Finney J; Meier A; Mure M
Biochemistry; 2018 Dec; 57(51):6973-6983. PubMed ID: 30499665
[TBL] [Abstract][Full Text] [Related]
13. Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition.
Millanes-Romero A; Herranz N; Perrera V; Iturbide A; Loubat-Casanovas J; Gil J; Jenuwein T; García de Herreros A; Peiró S
Mol Cell; 2013 Dec; 52(5):746-57. PubMed ID: 24239292
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR
Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967
[TBL] [Abstract][Full Text] [Related]
15. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer.
Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y
Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417
[TBL] [Abstract][Full Text] [Related]
16. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
[TBL] [Abstract][Full Text] [Related]
17. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
[TBL] [Abstract][Full Text] [Related]
18. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH
Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348
[TBL] [Abstract][Full Text] [Related]
19. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
[TBL] [Abstract][Full Text] [Related]
20. Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression.
Lu X; Xin DE; Du JK; Zou QC; Wu Q; Zhang YS; Deng W; Yue J; Fan XS; Zeng Y; Cheng X; Li X; Hou Z; Mohan M; Zhao TC; Lu X; Chang Z; Xu L; Sun Y; Zu X; Zhang Y; Chinn YE
Cancer Res; 2022 Dec; 82(23):4400-4413. PubMed ID: 36197797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
